[1]. Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer.
eLife [巻]10 (2021年) [査読] 有
[DOI] [2]. Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
Journal of cancer research and clinical oncology (2022年) [査読] 有
[DOI] [3]. MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.
NPJ precision oncology [巻]6 [号]1 [頁]88 (2022年) [査読] 有
[DOI] [4]. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Cancer immunology, immunotherapy : CII (2023年) [査読] 有
[DOI] [5]. Longitudinal Assessment of Real-World Treatments and Outcomes in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter, Prospective, Observational Study
European Journal of Respiratory Medicine (2024年) [査読] 有